A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.

scientific article published in June 2004

A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.CLIM.2003.11.002
P698PubMed publication ID15183151

P50authorYassine J DaoudQ80171578
P2093author name stringC Stephen Foster
A Razzaque Ahmed
Elisabetta Miserocchi
William Christen
Erik Letko
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectcicatricial pemphigoidQ627291
P304page(s)303-310
P577publication date2004-06-01
P1433published inClinical ImmunologyQ15752921
P1476titleA nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies
P478volume111

Reverse relations

cites work (P2860)
Q38980040Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management
Q36711702Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology
Q38766862Chronic Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: The Role of Systemic Immunomodulatory Therapy
Q36264883Clinical uses of intravenous immunoglobulin.
Q36794149Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders
Q39608977European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology
Q38776260European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology.
Q33385332Evidence for the use of intravenous immunoglobulins--a review of the literature
Q37532013High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases
Q36958343Human immunoglobulins in intraocular inflammation
Q24250186Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita
Q36359703Intravenous immunoglobulin in eye involvement
Q37933423Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update
Q36757383Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.
Q49833864Mucous membrane pemphigoid
Q46661473Mucous membrane pemphigoid with ocular involvement. Part II: therapy
Q64230980Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment
Q36168693Ocular cicatricial pemphigoid: manifestations and management
Q37264280Ocular mucous membrane pemphigoid: diagnosis and management strategies.
Q43789787Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid
Q38067153Pemphigoid diseases
Q39096598The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.
Q28067526The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature
Q36986054The use of i.v. IG therapy in dermatology
Q36960643Treatment of pyoderma gangrenosum with intravenous immunoglobulin
Q41359384Treatment strategies in mucous membrane pemphigoid
Q38169809Urban legend series: mucous membrane pemphigoid
Q83154740[Indications for intravenous immunoglobulins]
Q81317771[Intravenous immunoglobulins: therapeutic indications]

Search more.